Cargando…

Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients

OBJECTIVES: Hepatic hydrothorax (HH) is a predictor of poor survival in cirrhosis patients. However, whether HH increases the mortality risk of cirrhosis patients treated with transjugular intrahepatic portosystemic shunt (TIPS) is unknown. Our objective was to evaluate the influence of HH on the su...

Descripción completa

Detalles Bibliográficos
Autores principales: Gou, Xiaoyuan, Jia, Wenyuan, He, Chuangye, Yuan, Xulong, Niu, Jing, Xu, Jiao, Han, Na, Zhu, Ying, Wang, Wenlan, Tie, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121519/
https://www.ncbi.nlm.nih.gov/pubmed/36576548
http://dx.doi.org/10.1007/s00330-022-09357-3
_version_ 1785029387316363264
author Gou, Xiaoyuan
Jia, Wenyuan
He, Chuangye
Yuan, Xulong
Niu, Jing
Xu, Jiao
Han, Na
Zhu, Ying
Wang, Wenlan
Tie, Jun
author_facet Gou, Xiaoyuan
Jia, Wenyuan
He, Chuangye
Yuan, Xulong
Niu, Jing
Xu, Jiao
Han, Na
Zhu, Ying
Wang, Wenlan
Tie, Jun
author_sort Gou, Xiaoyuan
collection PubMed
description OBJECTIVES: Hepatic hydrothorax (HH) is a predictor of poor survival in cirrhosis patients. However, whether HH increases the mortality risk of cirrhosis patients treated with transjugular intrahepatic portosystemic shunt (TIPS) is unknown. Our objective was to evaluate the influence of HH on the survival of cirrhosis patients after TIPS. METHODS: Cirrhosis patients with portal hypertension complications were selected from a prospective database of consecutive patients treated with TIPS in Xijing Hospital from January 2015 to June 2021. Cirrhosis patients with HH were treated as the experimental group. A control group of cirrhosis patients without HH was created using propensity score matching. Survival after TIPS and the related risk factors were analysed. RESULTS: There were 1292 cirrhosis patients with portal hypertension complications treated with TIPS, among whom 255 patients had HH. Compared with patients without HH, patients with HH had worse liver function (MELD, 12 vs. 10, p < 0.001), but no difference in survival after TIPS was observed. After propensity score matching, 243 patients with HH and 243 patients without HH were enrolled. There was no difference in cumulative survival between patients with and without HH. Cox regression analysis showed that HH was not associated with survival after TIPS, and main portal vein thrombosis (> 50%) was a prognostic factor of long-term survival after TIPS in cirrhosis patients (hazard ratio, 1.386; 95% CI, 1.030–1.865, p = 0.031). CONCLUSION: Hepatic hydrothorax does not increase the risk of death after TIPS in cirrhosis patients. KEY POINTS: • Hepatic hydrothorax is a decompensated event of cirrhosis and increases the risk of death. • Hepatic hydrothorax is associated with worse liver function. • Hepatic hydrothorax does not increase the mortality of cirrhosis treated with TIPS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-022-09357-3.
format Online
Article
Text
id pubmed-10121519
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-101215192023-04-23 Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients Gou, Xiaoyuan Jia, Wenyuan He, Chuangye Yuan, Xulong Niu, Jing Xu, Jiao Han, Na Zhu, Ying Wang, Wenlan Tie, Jun Eur Radiol Vascular-Interventional OBJECTIVES: Hepatic hydrothorax (HH) is a predictor of poor survival in cirrhosis patients. However, whether HH increases the mortality risk of cirrhosis patients treated with transjugular intrahepatic portosystemic shunt (TIPS) is unknown. Our objective was to evaluate the influence of HH on the survival of cirrhosis patients after TIPS. METHODS: Cirrhosis patients with portal hypertension complications were selected from a prospective database of consecutive patients treated with TIPS in Xijing Hospital from January 2015 to June 2021. Cirrhosis patients with HH were treated as the experimental group. A control group of cirrhosis patients without HH was created using propensity score matching. Survival after TIPS and the related risk factors were analysed. RESULTS: There were 1292 cirrhosis patients with portal hypertension complications treated with TIPS, among whom 255 patients had HH. Compared with patients without HH, patients with HH had worse liver function (MELD, 12 vs. 10, p < 0.001), but no difference in survival after TIPS was observed. After propensity score matching, 243 patients with HH and 243 patients without HH were enrolled. There was no difference in cumulative survival between patients with and without HH. Cox regression analysis showed that HH was not associated with survival after TIPS, and main portal vein thrombosis (> 50%) was a prognostic factor of long-term survival after TIPS in cirrhosis patients (hazard ratio, 1.386; 95% CI, 1.030–1.865, p = 0.031). CONCLUSION: Hepatic hydrothorax does not increase the risk of death after TIPS in cirrhosis patients. KEY POINTS: • Hepatic hydrothorax is a decompensated event of cirrhosis and increases the risk of death. • Hepatic hydrothorax is associated with worse liver function. • Hepatic hydrothorax does not increase the mortality of cirrhosis treated with TIPS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-022-09357-3. Springer Berlin Heidelberg 2022-12-28 2023 /pmc/articles/PMC10121519/ /pubmed/36576548 http://dx.doi.org/10.1007/s00330-022-09357-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Vascular-Interventional
Gou, Xiaoyuan
Jia, Wenyuan
He, Chuangye
Yuan, Xulong
Niu, Jing
Xu, Jiao
Han, Na
Zhu, Ying
Wang, Wenlan
Tie, Jun
Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients
title Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients
title_full Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients
title_fullStr Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients
title_full_unstemmed Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients
title_short Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients
title_sort hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients
topic Vascular-Interventional
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121519/
https://www.ncbi.nlm.nih.gov/pubmed/36576548
http://dx.doi.org/10.1007/s00330-022-09357-3
work_keys_str_mv AT gouxiaoyuan hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients
AT jiawenyuan hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients
AT hechuangye hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients
AT yuanxulong hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients
AT niujing hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients
AT xujiao hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients
AT hanna hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients
AT zhuying hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients
AT wangwenlan hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients
AT tiejun hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients